Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Rev Esp Enferm Dig ; 114(12): 760-761, 2022 12.
Article in English | MEDLINE | ID: mdl-35656914

ABSTRACT

The assessment of the personal care received is an indicator of the quality of the health care system. The diagnosis of celiac disease generates concern in the patient and limits the quality of life, and adherence to treatment determines symptomatic improvement. For this reason, a nursing consultation for health and nutritional education for celiac patients has been set up in our hospital. The objectives were to know the degree of patient´s satisfaction of this health program regarding technical and communicative aspects, as well as to assess the influence of adherence to the gluten-free diet (GFD) on health through clinical and analytical parameters. This is a descriptive cross-sectional observational study in patients diagnosed of celiac disease from January 2019 to June 2021 according to the Catassi criteria and who have attended the nursing consultation. Subsequently, the satisfaction survey was carried out and the clinical and analytical results were analyzed descriptively and statistically using the Student's t-test. The satisfaction of the nursing consultation was higher than 90%, highlighting aspects such as the clarity of the information, the interest and the kindness of the healthcare professionals. About 94.5% of the patients showed clinical improvement after the health education and the levels of hemoglobin, ferritin and vitamin B12 increased significantly in the analytical control after the GFD.


Subject(s)
Celiac Disease , Gastroenterology , Humans , Celiac Disease/diagnosis , Patient Satisfaction , Quality of Life , Cross-Sectional Studies , Diet, Gluten-Free , Referral and Consultation , Patient Compliance
2.
Rev Esp Enferm Dig ; 114(5): 308, 2022 05.
Article in English | MEDLINE | ID: mdl-35067064

ABSTRACT

We present the case of a 40-year-old male sent for fatigue, mild weight loss and rectal bleeding for 2 months, neither fever nor diarrhea. He referred unprotected intercourse. Blood test revealed mild elevation of transaminases. We requested serologies, with positive CMV IgG and CMV plasma levels of 47UI/ml (PCR), and a negative result of the rest of hepatotropic viruses. Abdominal ultrasound was normal and during colonoscopy we observed an ulcer in lower rectum, with negative biopsies for malignancy and a positive immunohistochemistry (IHC) for CMV. We amplified the serologic analysis and detected positive antibodies for the human immunodeficiency virus (HIV), with a viral load of 50500 copies/ml, negative p24 antigen and CD4+ cell count of 900 cells/mm3 (30%). Rest of serologies and triple-site testing were negative. We referred the patient to the infectious disease consultation and they started antiretroviral therapy (ART). We decided a watchful waiting approach for the rectal ulcer with close endoscopic follow-up, with early healing and complete resolution.


Subject(s)
Colonic Diseases , Cytomegalovirus Infections , HIV Infections , Rectal Diseases , Adult , CD4 Lymphocyte Count , Cytomegalovirus , Cytomegalovirus Infections/complications , HIV Infections/complications , Humans , Male , Rectal Diseases/etiology , Ulcer/etiology
3.
Dig Liver Dis ; 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38839456

ABSTRACT

BACKGROUND: The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of these drugs in this context. METHODS: Crohn's disease patients who had received ustekinumab or vedolizumab for the indication of active complex perianal fistula, were included. Clinical remission was defined according to Fistula Drainage Assessment Index (no drainage through the fistula upon gentle pressure) based on physicians' assessment. RESULTS: Of 155 patients, 136 received ustekinumab, and 35 vedolizumab (16 received both). Median follow-up for ustekinumab was 27 months. Among those on ustekinumab, 54 % achieved remission, and within this group, 27 % relapsed during follow-up. The incidence rate of relapse was 11 % per patient-year. Multivariate analysis found no variables associated with treatment discontinuation or relapse. Median follow-up time for patients receiving vedolizumab was 19 months. Remission was achieved in 46 % of the patients receiving vedolizumab, and among them, 20 % relapsed during follow-up. The incidence rate of relapse was 7 % per patient-year. Adverse events were mild in 6 % on ustekinumab and 8 % on vedolizumab. CONCLUSION: Ustekinumab and vedolizumab appear effective, achieving remission in around half of complex perianal fistula patients, with favorable safety profiles.

4.
Rev Esp Salud Publica ; 972023 Aug 24.
Article in Spanish | MEDLINE | ID: mdl-37970866

ABSTRACT

OBJECTIVE: Eosinophilic esophagitis is actually the main cause of dysphagia in adults. The choise of therapy must be agreed with the patient. The objective of this study was to review the scientific literature to determine the efficacy of the different therapeutic options for eosinophilic esophagitis in adults. METHODS: A search for articles was carried out during the month of February 2023 in the databases PubMed, Web of Science, Scopus and Scielo using the search terms: eosinophilic esophagitis, therapeutics and treatment. Clinical trials and observational studies published in the last ten years in adults were selected. RESULTS: A total of 1,138 articles were obtained, of which 41 were selected after applying the eligibility criteria. Of the available therapies, the most frequently analyzed treatment was swallowed corticosteroids, followed by elimination diets and proton pump inhibitors. Clinical trials predominated. The studies show results on the efficacy of these therapies in histological and clinical remission, both in induction and in the long-term. CONCLUSIONS: There are basically three therapies for eosinophilic esophagitis in adults, all of them are superior to placebo in histological and clinical response.


OBJETIVO: La esofagitis eosinofílica es hoy en día la principal causa de disfagia en el adulto. La elección de la terapia se debe consensuar con el paciente. El objetivo de este trabajo fue revisar la bibliografía científica para conocer la eficacia de las distintas opciones terapéuticas de la esofagitis eosinofílica en el adulto. METODOS: Se realizó una búsqueda de artículos durante el mes de febrero de 2023 en las bases de datos de PubMed, Web of Science, Scopus y Scielo, empleando los términos de búsqueda eosinophilic esophagitis, therapeutics y treatment, seleccionándose los ensayos clínicos y estudios observacionales publicados en los últimos diez años en adultos. RESULTADOS: Se obtuvieron un total de 1.138 artículos, de los cuales 41 fueron seleccionados tras aplicar los criterios de elegibilidad. De las terapias disponibles, el tratamiento más frecuentemente analizado fueron los corticoides deglutidos, seguido de las dietas de eliminación y de los inhibidores de la bomba de protones, predominando los ensayos clínicos. Los estudios arrojan resultados sobre la eficacia de estas terapias en la remisión histológica y clínica, tanto en la inducción como a largo plazo. CONCLUSIONES: Existen fundamentalmente tres terapias en la esofagitis eosinofílica en el adulto, siendo todas superiores frente a placebo en respuesta histológica y clínica.


Subject(s)
Eosinophilic Esophagitis , Adult , Humans , Eosinophilic Esophagitis/drug therapy , Spain , Proton Pump Inhibitors/therapeutic use
5.
J Crohns Colitis ; 15(11): 1846-1851, 2021 Nov 08.
Article in English | MEDLINE | ID: mdl-33860795

ABSTRACT

BACKGROUND AND AIMS: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. METHODS: Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. RESULTS: A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% of patients in remission]. In the multivariate analysis, elevated serum C-reactive protein was the only variable significantly associated with lower likelihood of achieving remission. Remission was achieved in 39% and 33% of patients at Weeks 24 and 52, respectively; 36% of patients discontinued the treatment with ustekinumab during a median follow-up of 31 weeks. The probability of maintaining ustekinumab treatment was 87% at Week 16, 63% at Week 56, and 59% at Week 72; primary failure was the main reason for ustekinumab discontinuation. No variable was associated with risk of discontinuation. Three patients reported adverse events; one of them had a fatal severe SARS-CoV-2 infection. CONCLUSIONS: Ustekinumab is effective in both the short and the long term in real life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab.


Subject(s)
Colitis, Ulcerative/drug therapy , Ustekinumab/therapeutic use , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Prospective Studies , Registries , Remission Induction , Ustekinumab/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL